EsoCap AG hosted a well-attended virtual Investigators’ Meeting for the ACESO study on March 18, 2021.
ACESO is a randomized, placebo-controlled, double-blind trial evaluating the efficacy, tolerability and safety of ESO-101 in adult patients with active EoE (eosinophilic esophagitis).
The meeting brought together physicians, study nurses and study coordinators from 14 clinics in four countries with the teams from EsoCap and the FGK CRO (Contract Research Organization).
